GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (NAS:IONS) » Definitions » Cyclically Adjusted FCF per Share

Ionis Pharmaceuticals (Ionis Pharmaceuticals) Cyclically Adjusted FCF per Share : $0.31 (As of Dec. 2023)


View and export this data going back to 1991. Start your Free Trial

What is Ionis Pharmaceuticals Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Ionis Pharmaceuticals's adjusted free cash flow per share for the three months ended in Dec. 2023 was $0.229. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.31 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Ionis Pharmaceuticals's average Cyclically Adjusted FCF Growth Rate was -47.50% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -17.40% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 18.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Ionis Pharmaceuticals was 84.20% per year. The lowest was -17.40% per year. And the median was 9.40% per year.

As of today (2024-04-27), Ionis Pharmaceuticals's current stock price is $41.59. Ionis Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $0.31. Ionis Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is 134.16.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Ionis Pharmaceuticals was 5829.00. The lowest was 39.84. And the median was 105.20.


Ionis Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Ionis Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Ionis Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.45 0.55 0.75 0.59 0.31

Ionis Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.59 0.51 0.41 0.27 0.31

Competitive Comparison of Ionis Pharmaceuticals's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Ionis Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ionis Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Ionis Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Ionis Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ionis Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.229/129.4194*129.4194
=0.229

Current CPI (Dec. 2023) = 129.4194.

Ionis Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -0.291 99.695 -0.378
201406 -0.316 100.560 -0.407
201409 0.004 100.428 0.005
201412 0.557 99.070 0.728
201503 -0.373 99.621 -0.485
201506 0.478 100.684 0.614
201509 0.277 100.392 0.357
201512 -0.336 99.792 -0.436
201603 -0.637 100.470 -0.821
201606 -0.316 101.688 -0.402
201609 0.179 101.861 0.227
201612 -0.253 101.863 -0.321
201703 0.948 102.862 1.193
201706 -0.036 103.349 -0.045
201709 0.072 104.136 0.089
201712 0.105 104.011 0.131
201803 0.080 105.290 0.098
201806 3.826 106.317 4.657
201809 -0.224 106.507 -0.272
201812 0.784 105.998 0.957
201903 0.731 107.251 0.882
201906 -0.231 108.070 -0.277
201909 -0.213 108.329 -0.254
201912 1.460 108.420 1.743
202003 -0.126 108.902 -0.150
202006 -0.398 108.767 -0.474
202009 -0.166 109.815 -0.196
202012 0.651 109.897 0.767
202103 -0.410 111.754 -0.475
202106 -0.489 114.631 -0.552
202109 -0.426 115.734 -0.476
202112 1.414 117.630 1.556
202203 -0.248 121.301 -0.265
202206 -0.159 125.017 -0.165
202209 -0.222 125.227 -0.229
202212 -1.445 125.222 -1.493
202303 -1.021 127.348 -1.038
202306 -0.772 128.729 -0.776
202309 -0.783 129.860 -0.780
202312 0.229 129.419 0.229

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Ionis Pharmaceuticals  (NAS:IONS) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Ionis Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=41.59/0.31
=134.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Ionis Pharmaceuticals was 5829.00. The lowest was 39.84. And the median was 105.20.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Ionis Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Ionis Pharmaceuticals's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Ionis Pharmaceuticals (Ionis Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
Executives
Brian Birchler officer: EVP, Corp and Development Ops C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Patrick R. O'neil officer: SVP, Legal and General Counsel C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Onaiza Cadoret-manier officer: Chief Corp Dev and Cml Officer 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Eugene Schneider officer: EVP, Chf Clinical Develop Offc C/O IONIS PHARMACEUTICALS, 2855 GAZELLE CT, CARLSBAD CA 92010
Joseph Baroldi officer: Chief Business Officer C/O IONIS PHARMACEUTICALS, INC., C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Eric Swayze officer: SVP, Research 2855 GAZELLE COURT, 2855 GAZELLE COURT, CARLSBAD CA 92010
Brett P Monia director, officer: Senior Vice President 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Richard S Geary officer: Senior Vice President 2855 GAZELLE COURT, 2855 GAZELLE COURT, CARLSBAD CA 92010
Elizabeth L Hougen officer: SVP, Finance and CFO 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
C Frank Bennett officer: Vice President 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
B Lynne Parshall director, officer: Executive Vice President, CFO 2855 GAZELLE COURT, CARLSBAD CA 92010
Joseph Iii Klein director C/O GENAISSANCE PHARMACEUTICALS INC, FIVE SCIENCE PARK, NEW HAVEN CT 06511
Allene M. Diaz director C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Spencer R Berthelsen director 2855 GAZELLE COURT, CARLSBAD CA 92010
Frederick T Muto director 2855 GAZELLE COURT, CARLSBAD CA 92010